Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species
- PMID: 11083664
- PMCID: PMC90229
- DOI: 10.1128/AAC.44.12.3478-3480.2000
Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species
Abstract
After oral administration of 500 mg of levofloxacin to 12 volunteers, we investigated the pharmacokinetics and serum bactericidal activities (SBAs) against five strains of members of the family Enterobacteriaceae. Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg. h/liter; elimination half-life 4.23 +/- 0.87 h. SBAs were present for 24 h against Escherichia coli and Citrobacter freundii. The SBAs at 1, 12, and 24 h after administration against E. coli were 1:108, 1:29, and 1:7, respectively, and those against Citrobacter freundii were 1:74, 1:25, and 1:7, respectively. The SBAs were present for 12 h against the other three organisms tested. The SBAs against Serratia marcescens were 1:28 and 1:9 at 1 and 12 h, respectively; the SBAs against Klebsiella pneumoniae were 1:25 and 1:7 at 1 and 12 h, respectively; and the SBAs against Enterobacter cloacae were 1:24 and 1:10 at 1 and 12 h, respectively.
Similar articles
-
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.J Antimicrob Chemother. 2006 Nov;58(5):960-5. doi: 10.1093/jac/dkl356. Epub 2006 Aug 26. J Antimicrob Chemother. 2006. PMID: 16936293
-
Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters.J Antimicrob Chemother. 1999 Jun;43 Suppl C:71-5. doi: 10.1093/jac/43.suppl_3.71. J Antimicrob Chemother. 1999. PMID: 10404342
-
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.J Chemother. 2005 Oct;17(5):484-92. doi: 10.1179/joc.2005.17.5.484. J Chemother. 2005. PMID: 16323436
-
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.J Antimicrob Chemother. 1999 Jan;43(1):79-86. doi: 10.1093/jac/43.1.79. J Antimicrob Chemother. 1999. PMID: 10381104
-
Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.Drugs. 2003;63(24):2769-802. doi: 10.2165/00003495-200363240-00008. Drugs. 2003. PMID: 14664657 Review.
Cited by
-
The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.Ann Transl Med. 2019 Dec;7(23):779. doi: 10.21037/atm.2019.11.33. Ann Transl Med. 2019. PMID: 32042795 Free PMC article.
-
Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.Antimicrob Agents Chemother. 2003 Jan;47(1):413-5. doi: 10.1128/AAC.47.1.413-415.2003. Antimicrob Agents Chemother. 2003. PMID: 12499227 Free PMC article.
-
In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Ann Clin Microbiol Antimicrob. 2009 May 21;8:18. doi: 10.1186/1476-0711-8-18. Ann Clin Microbiol Antimicrob. 2009. PMID: 19460166 Free PMC article.
-
Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):395-402. doi: 10.1007/s13318-015-0271-8. Epub 2015 Mar 10. Eur J Drug Metab Pharmacokinet. 2016. PMID: 25753830
References
-
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
-
- Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis. 1998;26:1–12. - PubMed
-
- Davis R, Bryson H M. Levofloxacin—a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994;47:677–700. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources